Dengue Fever Outbreak: Symptoms, Prevention & New Vaccines in Brazil

The convergence of warmer temperatures and frequent rainfall across Brazil is creating ideal conditions for the Aedes aegypti mosquito to thrive, significantly increasing the risk of dengue fever transmission. This combination provides ample breeding grounds for the mosquito, which lays its eggs in stagnant water, and accelerates its reproductive cycle.

Recent data from Brazil’s Ministry of Health indicates a concerning rise in dengue cases. In the first seven weeks of 2026, the country recorded over 95,000 probable cases, with 18 deaths confirmed and another 115 under investigation. São Paulo state currently reports the highest number of probable cases, around 17,000, followed closely by Goiás with over 16,000 cases being analyzed. You can find more information about dengue in Brazil from the Ministry of Health here.

Projected Case Numbers and Regional Hotspots

Experts predict a substantial increase in dengue cases throughout the 2025-2026 season, spanning epidemiological weeks 41 of the previous year to week 40 of the current year. The InfoDengue-Mosqlimate Dengue Challenge (IMDC), a collaborative effort involving the Oswaldo Cruz Foundation (Fiocruz) and the Getulio Vargas Foundation (FGV), estimates a total of 1.8 million cases. A significant portion of these cases – 54% – are expected to concentrate in São Paulo, with an additional 10% occurring in Minas Gerais. This concentration highlights the need for targeted prevention and control measures in these regions.

Understanding Dengue and its Symptoms

Dengue is an arboviral disease, meaning it’s transmitted by arthropods – in this case, mosquitoes. The Aedes aegypti mosquito is the primary vector for dengue in Brazil, as well as for chikungunya and Zika viruses. The mosquito is easily identifiable by the white markings on its legs and thorax, often described as resembling a lyre. It’s a domestic mosquito, breeding in and around homes, schools, and workplaces. The Ministry of Health provides detailed information about the Aedes aegypti mosquito, including its lifecycle and habits.

While many dengue infections are asymptomatic or cause mild, flu-like symptoms, the virus has four distinct serotypes. This means that individuals can contract dengue multiple times, with subsequent infections potentially leading to more severe illness. Initial symptoms typically include high fever, body aches, skin rash, and fatigue. A key distinguishing feature is pain behind the eyes, caused by systemic inflammation triggered by the virus. In some cases, dengue can affect the retina, leading to blurred vision, visual disturbances, and light sensitivity, as explained by ophthalmologist Renata Alves.

More severe symptoms can include intense abdominal pain, vomiting, bleeding from the gums or nose, and a drop in body temperature. Cardiologist Ruldney Ray Oliveira cautions that dengue can also impact the cardiovascular system, potentially causing inflammation of the heart muscle, arrhythmias, and low blood pressure.

The Importance of Avoiding Self-Treatment

Currently, there is no specific antiviral treatment for dengue. Management focuses on supportive care, including rest and fluid intake. Seeking medical attention promptly at the onset of symptoms is crucial. Self-medication can be dangerous, particularly with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, diclofenac, and aspirin, as these can increase the risk of bleeding. Masking symptoms with medication can delay accurate diagnosis and appropriate care.

Advances in Dengue Prevention: Vaccination and Wolbachia

Significant progress is being made in dengue prevention through vaccination and innovative biological control methods. In 2024, a Japanese dengue vaccine began being administered to adolescents in Brazil through the Unified Health System (SUS). More recently, in late 2025, Brazil achieved a landmark milestone with the approval by the National Health Surveillance Agency (Anvisa) of the country’s first domestically developed dengue vaccine, created by the Butantan Institute. This single-dose vaccine offers protection against all four dengue serotypes.

Initial vaccine rollout is strategically focused on Maranguape (Ceará), Nova Lima (Minas Gerais), and Botucatu (São Paulo), targeting individuals aged 15 to 59, as well as healthcare professionals nationwide. The expectation is that the vaccine will become more widely available in the near future.

Beyond vaccination, the Wolbachia method is being employed to reduce dengue transmission. This involves introducing the Wolbachia bacteria into Aedes aegypti populations. The presence of Wolbachia prevents the mosquito from transmitting dengue, Zika, and chikungunya viruses.

Community Action: Preventing Mosquito Breeding

Effective dengue control relies heavily on community participation in eliminating mosquito breeding sites. This includes removing standing water from containers like vases, bottles, tires, gutters, and household items. Keeping water tanks covered and regularly cleaning swimming pools and plant saucers are also essential. Using window screens, repellents, and wearing protective clothing can further reduce the risk of mosquito bites.

Dengue is a serious public health concern, and a coordinated effort involving individuals, communities, and health authorities is vital to mitigate its impact. The increasing case numbers and potential for severe illness underscore the importance of vigilance and proactive prevention measures. For more information on dengue prevention and control, consult the Dengue – Instructions for Vector Control Personnel from the Ministry of Health.

Folha Universal, information for life!